Cargando…
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies
BACKGROUND: Bevacizumab is frequently combined with 5-fluorouracil-based chemotherapy for patients with metastatic colorectal cancer (mCRC). The relative benefit of bevacizumab in older patients has not been widely studied and is of interest. PATIENTS AND METHODS: This retrospective analysis used da...
Autores principales: | Cassidy, James, Saltz, Leonard B., Giantonio, Bruce J., Kabbinavar, Fairooz F., Hurwitz, Herbert I., Rohr, Ulrich-Peter |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2841755/ https://www.ncbi.nlm.nih.gov/pubmed/19904559 http://dx.doi.org/10.1007/s00432-009-0712-3 |
Ejemplares similares
-
Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2018) -
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
por: Garon, Edward B, et al.
Publicado: (2016) -
Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer
por: Burzykowski, Tomasz, et al.
Publicado: (2019) -
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
por: Okines, A, et al.
Publicado: (2009) -
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
por: Liu, Yingmiao, et al.
Publicado: (2013)